Richard Hubner
Impact in
- Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 150
- Pancreatic and Hepatic Oncology Research 81
- Lung Cancer Research Studies 47
- Colorectal Cancer Treatments and Studies 22
- Hepatology 20
- Hepatocellular Carcinoma Treatment and Prognosis 20
- Co-authors
- Richard S. HoulstonSanjay PopatJuan W. ValleÁngela LamarcaMairéad G. McNamaraW. David J. RyderJorge BarriusoMelissa Frizziero
- Journals
- Journal of Clinical Oncology (38 papers)Annals of Oncology (24 papers)Cancers (9 papers)Cancer Treatment Reviews (9 papers)British Journal of Cancer (8 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Richard Hubner
191 papers receiving 5.4k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Oncology 3.4k
- Hepatology 691
- Pathology and Forensic Medicine 1.5k
- Cancer Research 903
- Pulmonary and Respiratory Medicine 1.2k
Countries citing papers authored by Richard Hubner
This map shows the geographic impact of Richard Hubner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Hubner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Hubner more than expected).
Fields of papers citing papers by Richard Hubner
This network shows the impact of papers produced by Richard Hubner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Hubner. The network helps show where Richard Hubner may publish in the future.
Co-authors
The 25 scholars most cited alongside Richard Hubner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 3 | |
| 6 | 2023 | 2 | |
| 7 | 2023 | 7 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 0 | |
| 11 | 2023 | 3 | |
| 12 | 2023 | 1 | |
| 13 | 2023 | 3 | |
| 14 | 2021 | 6 | |
| 15 | 2021 | 5 | |
| 16 | 2020 | 73 | |
| 17 | 2020 | 19 | |
| 18 | 2018 | 17 | |
| 19 | Carboplatin-etoposide chemotherapy (CB-ET) for patients diagnosed with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): findings from a European Neuroendocrine Tumor Society Centre of Excellence. | 2018 | 1 |
| 20 | 2015 | 37 |
About Richard Hubner
Richard Hubner is a scholar working on Oncology, Hepatology, Epidemiology, Cancer Research and Neurology, having authored 199 papers that have together received 5.5k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (81 papers), Neuroendocrine Tumor Research Advances (57 papers), Lung Cancer Research Studies (47 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (36 papers), Neuroblastoma Research and Treatments (23 papers), Colorectal Cancer Treatments and Studies (22 papers), Cancer Genomics and Diagnostics (21 papers) and Hepatocellular Carcinoma Treatment and Prognosis (20 papers). The work is most often cited by research in Oncology (3.4k citations), Hepatology (691 citations), Pathology and Forensic Medicine (1.5k citations), Cancer Research (903 citations) and Pulmonary and Respiratory Medicine (1.2k citations). Richard Hubner has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Richard S. Houlston, Sanjay Popat, Juan W. Valle, Ángela Lamarca, Mairéad G. McNamara, W. David J. Ryder, Jorge Barriuso, Melissa Frizziero, Paul J. Ross and Andrea Wang‐Gillam. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancers, Cancer Treatment Reviews and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.